Quantcast

US Drug Watchdog Now Urges All US Transvaginal Mesh Failure Victims To Call Them For The Names Of The Best Possible Women Attorneys-No Other Group Offers This Service

September 19, 2012

The US Drug Watchdog is dramatically expanding their initiative focused on helping victims of a failed transvaginal mesh device-nationwide. The group worries because of the extremely sensitive nature of a transvaginal mesh failure there will be very little national news coverage of transvaginal mesh failures that involve potentially thousands of US women. According to court records a transvaginal mesh failure occurs when the mesh fails to bind to a woman’s pelvic tissues. As a consequence of this, the body rejects the mesh that has been sewn into it. As a result, the transvaginal mesh may start to poke its way through the vaginal wall and protrude out of the vaginal tissue. This complication is more commonly referred to as “erosion.” Erosion may result in extreme pain, infection, bleeding, vaginal discharge, with no possibility for sexual intercourse. The US Drug Watchdog has begun a very aggressive initiative designed to help a woman in any US state, who has had the transvaginal mesh surgical procedure done, and now has developed severe complications. Transvaginal mesh failure victims are urged to call the US Drug Watchdog anytime at 866-714-6466. As part of its initiative the US Drug Watchdog is offering to send all US women, who are victims of a transvaginal mesh failure to national caliber attorneys-who are all women. http://USDrugWatchdog.Com

(PRWEB) September 19, 2012

The US Drug Watchdog is now expanding their national initiative designed to help women recipients of transvaginal mesh, that is also called a sling, who are now severely damaged by a failure of this type of medical product. According to court records transvaginal mesh products were designed for women, who were suffering from pelvic organ prolapse, and or stress urinary incontinence. The procedure to install a transvaginal was supposed to be minimally-invasive. Court records also indicate transvaginal mesh failures are causing complications in patients such as erosion and infection. Women who experience transvaginal mesh failure may need to have numerous corrective surgeries, IV therapy, blood transfusions and drainage of hematomas or abscesses. The US Drug Watchdog is offering to help all US women, who are now victim’s of a transvaginal mesh failure get to the best possible attorneys, and the group is promising the attorneys will all be women. No other Group is offering a service like this. For more information victims of a transvaginal mesh failure are urged to contact the US Drug Watchdog anytime at 866-714-6466, or contact the group via their web site at http://USDrugWatchdog.Com

The US Drug Watchdog is indicating symptoms of a vaginal mesh implant failure may include:

  • Pain during sexual intercourse caused by erosion.
  • Mesh erosion through the vagina (the mesh is actually protruding out of the vaginal wall)
  • Bleeding
  • Vaginal Infection
  • Urinary problems
  • Organ perforation

The US Drug Watchdog says, “One of the biggest problems we have with respect to our failed medical device or recalled drug initiative work is the average US consumer never hears about a drug recall or failures such as medical devices failures like the transvaginal mesh products. If you have a friend, or loved one who is a recipient of a transvaginal mesh that has already failed or is showing symptoms of a failure, please have them call us at 866-714-6466. We want to make certain all transvaginal mesh failure victims get to the best possible attorneys, to ensure they get the best possible compensation for their ordeal, and we will do our absolute best to make certain all of the attorneys are women.” http://USDrugWatchdog.Com

U.S. District Court for the Southern District of West Virginia Multidistrict litigation (MDL) consolidates all similar cases into one courtroom and will include the Defendants:

C.R. Bard, Inc., (MDL No. 2187);

American Medical Systems Inc., MDL No. 2325);

Boston Scientific Corp., (MDL No. 2326); and Ethicon, Inc. (MDL No. 2327)

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9906728.htm


Source: prweb



comments powered by Disqus